Sang G L, Kovithavongs C, Ulan R, Kjellstrand C M
Department of Medicine, University of Alberta, Edmonton, Canada.
Am J Kidney Dis. 1997 May;29(5):669-77. doi: 10.1016/s0272-6386(97)90118-9.
Sodium ramping has been introduced as a technique to decrease side effects occurring during hemodialysis. We studied sodium ramping in 414 dialysis sessions in 23 patients by randomizing 2-week blocks of dialysis to either steady dialysate sodium of 140 mEq/L, linear sodium ramping during dialysis from 155 mEq/L to 140 mEq/ L, or stepwise ramping (sodium of 155 mEq/L for 3 hours and 140 mEq/L for 1 hour). We studied the number and severity of hypotensive and hypertensive episodes. A hypotensive episode was defined as an abrupt decline of systolic blood pressure of more than 50 mm Hg, a decrease in blood pressure accompanied by symptoms requiring intervention, or systolic blood pressure of less than 90 mm Hg even without symptoms. A hypertensive episode was defined as a sudden increase in systolic blood pressure of over 30 mm Hg. We also recorded other side effects (headache, cramps, nausea, vomiting, dizziness, thirst, fatigue, weight gain, and blood pressure) during, immediately after, and between dialysis sessions. There was no major difference between the two ramping protocols, but compared with standard dialysis, both decreased total number of side effects from 4.0 to 3.0 (P = 0.057); the number of hypotensive episodes decreased from 1.3 to 0.7 (P = 0.036). The lowest blood pressure was 114/66 mm Hg during control and 123/69 mm Hg during ramping (P < 0.0001). The frequency of cramps during dialysis decreased from 0.9 to 0.5 (P = 0.006). There was no difference in headache, nausea, or vomiting. The number of hypertensive episodes increased from 0.045 to 0.086 during ramping (P = 0.125). Of 23 patients, only five (22%) had a marked decrease in symptoms; two of the three most symptomatic patients showed no significant improvement. Between dialysis sessions, patients complained of more fatigue and thirst (P < 0.0001 and P = 0.0028, respectively), and interdialytic weight gain following ramping was 5.1% of body weight compared with 4.4% without ramping (P < 0.0001). Blood pressure also increased following ramping, from 143/79 mm Hg to 152/81 mm Hg (P = 0.001). Ramping can decrease the overall number of side effects, but increases interdialytic symptoms, weight gain, and hypertension. In most instances, it simply changes the time the side effects occur. Only 22% of patients have significant benefit. These patients can be identified only through trial and error, as no model of these patients can be created.
钠浓度递增法已作为一种减少血液透析期间出现副作用的技术被引入。我们通过将为期2周的透析疗程随机分为以下三种情况,对23例患者的414次透析疗程进行了钠浓度递增法研究:透析液钠浓度稳定在140 mEq/L;透析期间钠浓度从155 mEq/L线性递增至140 mEq/L;或阶梯式递增(155 mEq/L的钠浓度持续3小时,140 mEq/L的钠浓度持续1小时)。我们研究了低血压和高血压发作的次数及严重程度。低血压发作被定义为收缩压突然下降超过50 mmHg、血压下降伴有需要干预的症状,或即使无症状收缩压低于90 mmHg。高血压发作被定义为收缩压突然升高超过30 mmHg。我们还记录了透析期间、透析刚结束后以及透析疗程之间的其他副作用(头痛、痉挛、恶心、呕吐、头晕、口渴、疲劳、体重增加和血压)。两种递增方案之间没有重大差异,但与标准透析相比,二者均使副作用总数从4.0降至3.0(P = 0.057);低血压发作次数从1.3降至0.7(P = 0.036)。对照期间最低血压为114/66 mmHg,递增期间为123/69 mmHg(P < 0.0001)。透析期间痉挛频率从0.9降至0.5(P = 0.006)。头痛、恶心或呕吐方面没有差异。递增期间高血压发作次数从0.045增至0.086(P = 0.125)。在23例患者中,只有5例(22%)症状明显减轻;症状最严重的3例患者中有2例没有显著改善。在透析疗程之间,患者抱怨更疲劳和口渴(分别为P < 0.0001和P = 0.0028),递增后透析间期体重增加为体重的5.1%,而未递增时为4.4%(P < 0.0001)。递增后血压也升高,从143/79 mmHg升至152/81 mmHg(P = 0.001)。递增法可以减少副作用的总数,但会增加透析间期症状、体重增加和高血压。在大多数情况下,它只是改变了副作用出现的时间。只有22%的患者有显著益处。由于无法建立这些患者的模型,只能通过反复试验来识别这些患者。